Filing Flows › Citius Pharmaceuticals (CTXR) › Q3 FY26
Citius Pharmaceuticals (CTXR) Q3 FY26 earnings results (third quarter fiscal 2026)
10-Q filed Aug 14, 2026
Citius Pharmaceuticals (CTXR) reported revenue of $1.5M for the third quarter fiscal 2026 (Q3 FY26) and -10% from the quarter before. Operating margin was -785.4%, net loss $11.9M (797.9% of revenue).
Citius Pharmaceuticals, Q3 FY26: revenue $1.5M, operating margin -785.4%, net loss $11.9M, operating cash flow −$8.7M. The chart follows the revenue to costs, profit and cash.
| Q3 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.5M | -10% | — |
| Operating profit | −$11.7M | — | — |
| Net earnings | −$11.9M | — | — |
| Operating cash flow | −$8.7M | — | — |
What changed
Revenue was $1.5M in Q3 FY26, down 10% from the previous quarter.
Gross margin was 67.1%. Operating costs exceeded revenue by $11.7M, an operating margin of -785.4%. The quarter ended with a net loss of $11.9M, narrower than the previous quarter's $28.1M loss. Minority interests bore $3.1M of it: to shareholders the quarter was a loss of $8.9M.
Operating cash flow was −$8.7M. Non-cash charges added back $3.8M of share-based compensation. Working capital and other items used $569K.
Questions
What was Citius Pharmaceuticals' revenue in the third quarter fiscal 2026?
Citius Pharmaceuticals (CTXR) reported revenue of $1.5M for the third quarter fiscal 2026 (Q3 FY26) and -10% from the quarter before.
Was Citius Pharmaceuticals profitable in the third quarter fiscal 2026?
Operating loss was $11.7M (-785.4% of revenue) and net loss $11.9M.